IMARC Group has recently released a new research study “Mammalian Polyclonal IgG Antibody Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.
What are the growth prospects of the Mammalian Polyclonal IgG Antibody Industry?
The global mammalian polyclonal IgG antibody market size reached US$ 984.81 Million in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1,351.73 Million by 2027, exhibiting a growth rate (CAGR) of 5.25% during 2022-2027.
What is a Mammalian Polyclonal IgG Antibody ?
Mammalian polyclonal immunoglobulins (IgG) antibody represents antigens or vaccinations manufactured through inoculation of various mammals, such as rabbits, mice, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in several immunoassay trials, including western blot tests, enzyme-linked immunosorbent assay (ELISA), immunoradiometric assay (IRMA), and radioimmunoassay (RIA).
Mammalian polyclonal IgG antibody is commercially available in cardiac, metabolic, and renal marker variants. It assists in creating multiple therapeutics, diagnosing various ailments, and performing identification and flow cytometry. As a result, mammalian polyclonal IgG antibody finds widespread applications in biochemical research to detect denatured proteins and study diseases and their treatments.
Impact of COVID-19:
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Request and get a sample brochure for free: https://www.imarcgroup.com/mammalian-polyclonal-igg-antibody-market/requestsample
What are the major market drivers in the Mammalian Polyclonal IgG Antibody Market ?
The escalating prevalence of several chronic disorders, such as cancer and autoimmune ailments, and the rising demand for antigens for multiple immunoassay tests and therapeutic and analytical applications in research settings are among the primary factors driving the mammalian polyclonal IgG antibody market. Besides this, the increasing investments in biotechnology and pharmaceutical companies to formulate effective novel vaccinations and injectables through advanced technologies are further augmenting the market growth.
Moreover, the continuous innovation of creative mammalian antibodies by biopharma organizations for quality control (QC) is catalyzing the global market. Apart from this, the expanding healthcare infrastructure and the extensive research and development (R&D) activities to enhance antigen efficacy are acting as significant growth-inducing factors.
Furthermore, the elevating requirement for biomarkers by clinicians for accurate and rapid diagnosis of B-cell lymphoma and leukemia is expected to bolster the mammalian polyclonal IgG antibody market in the coming years.
|Mammalian Polyclonal IgG Antibody Market Report Scope|
|Market size value in 2021||US$ 984.81 Million|
|Market forecast in 2027||US$ 1,351.73 Million|
|Growth Rate||CAGR of 5.25% from 2022 to 2027|
|Base year for estimation||2021|
|Report coverage||Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends|
|Segments covered||Type, Product, Application And End Use|
|Regional scope||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Key companies profiled||Abbiotec Inc., Abcam plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Creative Diagnostics, Elabscience Biotechnology Inc., Geno Technology Inc., Merck KGaA, Proteintech Group Inc., STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc.|
|Market Dynamics||Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,|
|Customization purview||If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.|
The report has been segmented the market into following categories:
Breakup by Type:
Breakup by Product:
- Cardiac Markers
- Metabolic Markers
- Renal Markers
Breakup by Application:
- Antibody Identification
- Western Blotting
Breakup by End Use:
- Diagnostic Centers
- Academic and Research Institutes
• North America (United States, Canada)
• Europe (Germany, France, United Kingdom,
Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia,
Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
List of Major Key Players:
The competitive landscape of the industry has
Bio-Rad Laboratories Inc.
Cell Signaling Technology Inc.
Elabscience Biotechnology Inc.
Geno Technology Inc.
Merck KGaA, Proteintech Group Inc.
STEMCELL Technologies Inc.
and Thermo Fisher Scientific Inc.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800